With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of
The latest business developments from across Europe & Middle East by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
growth, particularly in Europe and the Middle East.
Structural Data Platform to help Advance Treatments for Brain Disease
“We are delighted that Lundbeck has chosen our cloud platform for handling its structural knowledge. This decision shows the increasing importance of collaboration between medicinal and computational chemists,” said Eric Le Roux, founder and CEO of Discngine. “We believe that cloud computing will play an ever increasing role in pharmaceutical research, bringing signifi cant benefi ts to drug developers and eventually patients.”
Pharma company Lundbeck has become the fi rst business to select Discngine’s proprietary 3decision®
collaborative platform to manage
its structural knowledge related to protein and ligand 3D structures. The platform, which transforms raw data coming from 3D structures and biomolecular sequences into well-organized and easily accessible knowledge, will be used by Lundbeck to help with the discovery of new treatments for brain diseases.
“It’s important for us to have instant access to all internal and external structural data, and the 3decision platform is an outstanding tool for our purposes,” said Lena Tagmose, senior director, Molecular Design and Enabling Technologies at Lundbeck. “It’s time-and cost-effi cient and brings signifi cant advantages through instant accessibility and a wide range of data modelling options.” The development of the platform began three years ago in a co-operation with Abbvie and was launched as a commercial product in 2018. This year it received the BioIT World 2019 Innovative Practices Award.
50247pr@reply-direct.com £4.8 million Viral Vector Supply Chain Collaboration Completed
personalised medicine, the joint collaboration had a combined investment of £4.8 million including signifi cant support from a grant received under the UK Governments’ Innovate UK Health and Life Sciences Programme.
Peter Coleman, Chief Executive at Cobra Biologics, said: “The Innovate UK grant has enabled Cobra and Symbiosis to form a close partnership to provide a seamless viral vector service to the global community for both clinical and commercial supply. In conjunction with Symbiosis, we have now helped to establish the UK as world leader in this exciting fi eld.”
Peter Coleman Colin Mackay
The successful completion of an 18 month project between contract development and manufacturing organisation Cobra Biologics and CMO Symbiosis Pharmaceutical Services, has seen a signifi cant increase in both companies’ existing commercial capacity and simplifi cation of the supply chain process for manufacture of viral vectors for use in gene therapy and immunotherapy.
Intended to accelerate the clinical and commercial production of viral vectors, which represent part of the burgeoning Advanced Therapeutics Medicinal Product (ATMP) drug development space and the frontier of
Colin MacKay, Chief Executive of Symbiosis, added: “The strategic focus of Innovate UK in proactively supporting the development of a supply chain which aligns multiple service providers – such as Symbiosis and Cobra - to specifi cally enhance their joint means to facilitate the development of viral vectors and other ATMPs here in the UK is not only astute but will generate tangible value which will benefi t the UK, the CDMOs receiving grants alongside their respective clients, and ultimately the patients most in need of those innovative medicines.
“The relationship that Symbiosis and Cobra have forged during this grant collaboration project represents an excellent foundation for both companies to strengthen their aligned ability to develop world class personalised medicines more quickly for shared clients from around the world.”
50023pr@reply-direct.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
